circRNA-SORE/UBQLN1/GPX4 Mediates the Acquisition of Sorafenib Resistance in Hepatocellular Carcinoma Through Inhibition of Ferroptosis

Abstract

The clinical performance of targeted therapies for treating hepatocellular carcinoma (HCC) is significantly limited by the frequent emergence of drug resistance, ultimately resulting in therapeutic failure and poor prognosis. While the precise mechanisms underlying this resistance are not fully elucidated. Emerging evidence implicated that reactive oxygen species (ROS) homeostasis and ferroptosis, a unique form of programmed cell death, are closely associated with the development of drug resistance in cancer cells. In this study, we demonstrated that circRNA-SORE, a circRNA previously reported by our group, played a crucial role in mediating sorafenib resistance via regulating intracellular ROS levels and inhibiting ferroptosis. Mechanically, we identified that circRNA-SORE exerted its regulatory effects through modulating the level of UBQLN1. UBQLN1, via its STI domain, stabilized GPX4, a crucial antioxidant enzyme that protects against ferroptosis death. The stabilization of GPX4 promoted cancer cell survival under sorafenib-induced oxidative stress. In conclusion, this study revealed a novel circRNA-SORE/UBQLN1/GPX4 regulatory axis that mediated sorafenib resistance in HCC and also offered a promising therapeutic strategy to overcome drug resistance and improve clinical outcomes for patients with HCC.

Keywords

circRNA / ferroptosis / sorafenib resistance / UBQLN1:GPX4

References

[1] A. Villanueva, “Hepatocellular Carcinoma,” New England Journal of Medicine 391 (2019): 1301–1314.

[2] M. Pinter, C. A. M. Fulgenzi, D. J. Pinato, and B. Scheiner, “Systemic Treatment in Patients With Hepatocellular Carcinoma and Advanced Liver Dysfunction,” Gut 74, no. 7 (2025): 1178–1188.

[3] J. D. Gordan, E. B. Kennedy, G. K. Abou-Alfa, et al., “Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update,” Journal of Clinical Oncology 42, no. 15 (2024): 1830–1850.

[4] Y. Chen, S. Dai, C. Cheng, and L. Chen, “Lenvatinib and Immune-checkpoint Inhibitors in Hepatocellular Carcinoma: Mechanistic Insights, Clinical Efficacy, and Future Perspectives,” Journal of Hematology & Oncology 17 (2024): 130.

[5] S. Xia, Y. Pan, Y. Liang, J. Xu, and X. Cai, “The Microenvironmental and Metabolic Aspects of Sorafenib Resistance in Hepatocellular Carcinoma,” EBioMedicine 51 (2020): 102610.

[6] B. Gillissen, A. Richter, A. Richter, et al., “Bax/Bak-independent Mitochondrial Depolarization and Reactive Oxygen Species Induction by sorafenib Overcome Resistance to Apoptosis in Renal Cell Carcinoma,” Journal of Biological Chemistry 292 (2017): 6478–6492.

[7] A. K. Maiti, “Genetic Determinants of Oxidative Stress-mediated Sensitization of Drug-resistant Cancer Cells,” International Journal of Cancer 130 (2012): 1–9.

[8] F. Paech, C. Mingard, D. Grünig, V. F. Abegg, J. Bouitbir, and S. Krähenbühl, “Mechanisms of Mitochondrial Toxicity of the Kinase Inhibitors Ponatinib, Regorafenib and Sorafenib in human Hepatic HepG2 Cells,” Toxicology 395 (2018): 34–44.

[9] X. Chen, R. Kang, G. Kroemer, and D. Tang, “Broadening Horizons: The Role of Ferroptosis in Cancer,” Nature Reviews Clinical Oncology 18 (2021): 280–296.

[10] A. Beatty, T. Singh, Y. Y. Tyurina, et al., “Ferroptotic Cell Death Triggered by Conjugated Linolenic Acids Is Mediated by ACSL1,” Nature Communications 12 (2021): 2244.

[11] J. Xu, L. Ji, and Y. Liang, “CircRNA-SORE Mediates Sorafenib Resistance in Hepatocellular Carcinoma by Stabilizing YBX1,” Signal Transduction and Targeted Therapy 5 (2020): 1–14.

[12] J. Xu, L. Ji, Y. Liang, et al., “CircRNA-SORE Mediates Sorafenib Resistance in Hepatocellular Carcinoma by Stabilizing YBX1,” Signal Transduction and Targeted Therapy 5 (2020): 298.

[13] S. Dixon, K. Lemberg, M. Lamprecht, et al., “Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death,” Cell 149 (2012): 1060–1072.

[14] Y. Zhang, R. V. Swanda, L. Nie, et al., “mTORC1 couples Cyst(e)Ine Availability With GPX4 Protein Synthesis and Ferroptosis Regulation,” Nature Communications 12 (2021): 1589.

[15] H. Sies, “Ebselen, a Selenoorganic Compound as Glutathione Peroxidase Mimic,” Free Radical Biology and Medicine 14 (1993): 313–323.

[16] W. S. Yang and B. R. Stockwell, “Ferroptosis: Death by Lipid Peroxidation,” Trends in Cell Biology 26 (2016): 165–176.

[17] E. Itakura, E. Zavodszky, S. Shao, M. Wohlever, R. Keenan, and R. Hegde, “Ubiquilins Chaperone and Triage Mitochondrial Membrane Proteins for Degradation,” Molecular Cell 63 (2016): 21–33.

[18] Y. Liu, L. Lü, C. L. Hettinger, et al., “Ubiquilin-1 Protects Cells From Oxidative Stress and Ischemic Stroke Caused Tissue Injury in Mice,” Journal of Neuroscience 34 (2014): 2813–2821.

[19] Z. Kurlawala, P. P. Shah, C. Shah, and L. J. Beverly, “The STI and UBA Domains of UBQLN1 Are Critical Determinants of Substrate Interaction and Proteostasis,” Journal of Cellular Biochemistry 118 (2017): 2261–2270.

[20] C. Mao, X. Liu, Y. Zhang, et al., “DHODH-mediated Ferroptosis Defence Is a Targetable Vulnerability in Cancer,” Nature 593 (2021): 586–590.

[21] X. Sun, Z. Ou, R. Chen, et al., “Activation of the p62-Keap1-NRF2 Pathway Protects Against Ferroptosis in Hepatocellular Carcinoma Cells: Hepatobiliary Malignancies,” Hepatology 63 (2016): 173–184.

[22] X. Sun, X. Niu, R. Chen, et al., “Metallothionein-1G Facilitates Sorafenib Resistance Through Inhibition of Ferroptosis,” Hepatology 64 (2016): 488–500.

[23] J. Feng, P. Lu, G. Zhu, et al., “ACSL4 is a Predictive Biomarker of Sorafenib Sensitivity in Hepatocellular Carcinoma,” Acta Pharmacologica Sinica 42 (2021): 160–170.

[24] K. Bersuker, J. M. Hendricks, Z. Li, et al., “The CoQ Oxidoreductase FSP1 Acts Parallel to GPX4 to Inhibit Ferroptosis,” Nature 575 (2019): 688–692.

[25] W. Yang, R. SriRamaratnam, M. Welsch, et al., “Regulation of Ferroptotic Cancer Cell Death by GPX4,” Cell 156 (2014): 317–331.

[26] X. Chen, C. Yu, R. Kang, G. Kroemer, and D. Tang, “Cellular Degradation Systems in Ferroptosis,” Cell Death and Differentiation 28 (2021): 1135–1148.

[27] Y. Ding, X. Chen, C. Liu, et al., “Identification of a Small Molecule as Inducer of Ferroptosis and Apoptosis Through Ubiquitination of GPX4 in Triple Negative Breast Cancer Cells,” Journal of hematology & oncology 14 (2021): 19.

[28] J. Xu, H. Lin, G. Li, et al., “The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis Through Altering the Androgen Receptor Signals,” EBioMedicine 12 (2016): 55–67.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.